HC Wainwright Reiterates Buy Rating on NovoCure Limited
HC Wainwright maintains a buy rating on NovoCure with a $46 target.
Key Points
- On June 18, 2026, HC Wainwright reiterated its buy rating on NovoCure Limited with a $46 price target.
- NovoCure Limited trades at $14.71 on the NasdaqGS, with a market cap of $1.65 billion and a beta of 0.923.
- Insiders recently engaged in transactions, with CEO Frank Leonard selling shares on June 4, 2026.
On June 18, 2026, HC Wainwright reiterated its buy rating on NovoCure Limited (NASDAQ: NVCR), setting a price target of $46. Analyst Emily Bodnar emphasized the firm's positive outlook on the company's growth potential.
NovoCure Stock Snapshot
Shares of NovoCure Limited traded around $14.71 on the NasdaqGS. The company has a market cap of approximately $1.65 billion. Despite not being currently profitable, NovoCure is a player in the healthcare sector, specifically in medical devices, with a beta of 0.923. Over the past year, the stock has fluctuated between $9.82 and $18.92. Its 50-day moving average is $15.63, while the 200-day moving average stands at $13.35. The company maintains a current ratio of 2.903 and a quick ratio of 2.658, with a debt-to-equity ratio of 71.04.
Recent Earnings
For its most recent reporting period, NovoCure reported revenue of approximately $674.4 million, reflecting a growth of 12.3%. However, the company posted a net margin of -25.66% and a return on equity of -49.96%, indicating significant challenges in profitability. The next earnings report is expected on July 23, 2026.
Insider Buying and Selling at NovoCure Limited
Recent insider activity at NovoCure shows CEO Frank Leonard sold 34,273 shares at an average price of $17.93 on June 4, 2026. Meanwhile, other insiders such as Martin Madden, Anthony Vernon, Timothy Scannell, and David Hung collectively bought shares on June 3, 2026, signaling varied levels of insider confidence.
Analysts Set New Price Targets
HC Wainwright & Co. reiterated its buy rating on June 18, 2026, with a $46 price target. Additionally, Wells Fargo maintained a hold rating at a $17 target on May 4, 2026, and Evercore ISI Group kept a buy rating with a $20 target on May 1, 2026. Overall, the analyst consensus is a buy, with an average target price of $26.29 from seven analysts.
About NovoCure Limited
NovoCure Limited is a healthcare company based in Baar, Switzerland, specializing in the development, manufacture, and sale of tumor treating fields (TTFields) devices. These devices are used to treat solid tumor cancers, including glioblastoma and others. The company operates in the United States, Germany, France, Japan, Greater China, and internationally. With a workforce of 1,605 employees, Mr. Frank Leonard serves as the CEO.
Bottom Line
HC Wainwright's reiteration of a buy rating for NovoCure Limited underscores the firm's confidence in the company's technological advancements in cancer treatment. While the company faces profitability challenges, its innovative approach in the medical device sector continues to attract analyst attention. As always, it's important to note that analyst ratings are one of many factors investors consider, and this report reflects the firm's perspective as of June 18, 2026.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.